Cover Image
市場調查報告書

非何杰金氏淋巴瘤治療市場、開發平台考察

Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight

出版商 KuicK Research 商品編碼 319020
出版日期 內容資訊 英文 573 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
非何杰金氏淋巴瘤治療市場、開發平台考察 Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight
出版日期: 2014年11月19日 內容資訊: 英文 573 Pages
簡介

本報告提供非何杰金氏淋巴瘤治療市場相關調查、全球市場概要、治療機制、各種類、相位、企業的開發平台分析、開發平台藥物、成藥分析,及各國、年度、組成類別的專利分析等彙整,為您概述為以下內容。

第1章 非何杰金氏淋巴瘤的簡介

第2章 非何杰金氏淋巴瘤治療的機制

第3章 全球非何杰金氏淋巴瘤市場概要

  • 目前市場情況
  • 全球非何杰金氏淋巴瘤的臨床開發平台概要

第4章 全球非何杰金氏淋巴瘤市場動態

  • 可喜的市場參數
  • 市場成長課題
  • 未來的成長展望

第5章 濾泡型淋巴瘤的臨床實驗平台考察:各相位、適應症、企業、國家

  • 到第三階段為止的調查
  • 在開發平台中止的藥物

第6章 非何杰金氏淋巴瘤:各相位、適應症、企業、國家

第7章 B細胞淋巴瘤:各相位、適應症、企業、國家

第8章 被套細胞淋巴瘤:各相位、適應症、企業、國家

第9章 皮膚T細胞淋巴瘤:各相位、適應症、企業、國家

第10章 皮膚B細胞淋巴瘤:各相位、適應症、企業、國家

第11章 瀰漫性大型B細胞淋巴癌:各相位、適應症、企業、國家

第12章 T細胞淋巴瘤:各相位、適應症、企業、國家

第13章 蕈狀肉芽腫:各相位、適應症、企業、國家

第14章 末梢T細胞淋巴瘤:各相位、適應症、企業、國家

第15章 多發性非何杰金氏淋巴瘤:各相位、適應症、企業、國家

第16章 競爭情形

  • Aryogen Biopharma
  • Biogen Idec
  • Biovest International
  • Chugai Pharmaceutical
  • Genetech
  • ImmunoGen
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Roche

圖表清單

目錄

The market for Non Hodgkin Lymphoma has significant unmet medical necessities in terms of demand for innovative drugs and novel technologies. This is one of the major factors behind the market witnessing rapid growth in Non Hodgkin Lymphoma segment. Past few decades have witnessed an increased level of activity with regards to development of new identification systems and drug mechanisms. In recent years, there have been an increasing number of pharmaceutical companies focusing their efforts on developing better and highly effective therapeutics for Non Hodgkin Lymphoma which are likely to occupy major market share in coming years.

Monoclonal antibodies (mAbs) for the treatment of Non Hodgkin Lymphoma has occupied large portion in global market. The highly versatile nature of mAbs makes them suitable for targeting different sub-categories of Non Hodgkin Lymphoma which is modestly provided by other therapeutics. The market of widely used chemotherapeutics is likely to decrease further as they are less effective and have more side effects as compared to mAbs. Present market shows that pharmaceutical companies are trying to capture large market portion by increasing indication of already available mAbs for other cancer categories.

Targeted therapies for Non Hodgkin Lymphoma have been able to make a significant place in global market. These therapeutics are generally based on inhibitors which targets signaling in the cancerous cells. Ibrutinib kinase inhibitor developed by Pharmacyclics and Johnson and Johnson's sub-division Janssen Pharmaceuticals got market approval by the FDA in 2013 for the treatment of mantel cell lymphoma. In 2014, this drug also got the FDA's approval for chronic lymphocytic leukemia in US market. It is expected that more targeted therapeutics will be available in coming years that would be able to provide effective medical care to patients and generate higher revenues for pharmaceutical companies.

The concepts of personalized cancer vaccines for Non Hodgkin Lymphoma have started emerging in global therapeutic market. These vaccines are widely accepted by oncologists and patients for having higher safety and efficacy levels. However, issues pertaining higher costs of newly developed personalized cancer vaccine is expected to decrease in near future. Technological advances have created higher confidences in pharmaceutical companies to make these medicines at higher manufacturing rates. This capability will help them to increase the market penetration of Non Hodgkin Lymphoma cancer vaccines.

With the recent technological advances, stem cell transplant has emerged as potent method for the treatment and cure of Non-Hodgkin. Oncologists are still trying to decipher the underlying principal of stem cell therapeutics as a treatment strategy. This method is expected to emerge as major section in market as the benefits provided outmatches any other products. It is expected that pharmaceutical companies would be able to overcome barriers in coming years before market introduction.

The market of Non Hodgkin Lymphoma is expected to make steady growth in coming years due to raising incidences and introduction of new therapeutics by pharmaceutical companies in global market. This largely untapped market has yet to witness the products which would be able to prevent, cure this disease, decrease morbidity and mortality rates. Large amount of money invested in research and development has started to show positive effect on pharmaceutical industry. As a result, the introductions of large amount of therapeutic products in coming years are expected to increase global market size of Non Hodgkin Lymphoma therapeutics.

“Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight” Report Highlight:

  • Global Non Hodgkin Lymphoma Market Overview
  • Mechanism of Non Hodgkin Lymphoma Therapeutics
  • Global Non Hodgkin Lymphoma Pipeline by Type, Phase & Company
  • Global Non Hodgkin Lymphoma Pipeline: 204 Drugs
  • Majority of the Drugs are in Phase-I: 54 Drugs
  • Marketed Drugs for Non Hodgkin Lymphoma: 30 Drugs
  • Patent Analysis by Country, Year & Compositions

Table of Contents

1. Introduction to Non Hodgkin Lymphoma

  • 1.1. Low Grade Non Hodgkin Lymphomas-
  • 1.2. High Grade Non Hodgkin Lymphomas

2. Mechanism of Non Hodgkin Lymphoma Therapeutics

3. Global Non Hodgkin Lymphoma Market Overview

  • 3.1. Current Market Scenario
  • 3.2. Global Non Hodgkin Lymphoma Clinical Pipeline Overview

4. Global Non Hodgkin Lymphoma Market Dynamics

  • 4.1. Favorable Market Parameters
  • 4.2. Market Growth Challenges
  • 4.3. Future Growth Outlook

5. Follicular Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country

  • 5.1. Research till Phase-III
  • 5.2. Discontinued Drug in Pipeline

6. Non Hodgkin Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country

  • 6.1. Research till Registration
  • 6.2. Marketed Drugs Clinical Insight
  • 6.3. Suspended & Discontinued Drugs in Clinical Pipeline

7. B-Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country

  • 7.1. Preclinical till Phase-II
  • 7.2. Discontinued Drugs in Clinical Pipeline

8. Mantle Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country

  • 8.1. Preclinical till Phase-II
  • 8.2. Discontinued Drugs in Clinical Pipeline

9. Cutaneous T Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country

  • 9.1. Preclinical till Phase-II
  • 9.2. Marketed Drug Clinical Insight
  • 9.3. Discontinued Drugs in Clinical Pipeline

10. Cutaneous B-Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country

  • 10.1. Phase: Preclinical

11. Diffuse Large B Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country

  • 11.1. Preclinical till Phase-II
  • 11.2. Discontinued Drugs in Clinical Pipeline

12. T Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country

  • 12.1. Preclinical till Phase-II
  • 12.2. Marketed Drugs Clinical Insight
  • 12.3. Discontinued Drugs in Clinical Pipeline

13. Mycosis Fungoides Clinical Pipeline Insight by Phase, Indication, Company & Country

  • 13.1. Phase-I
  • 13.2. Marketed Drugs Clinical Insight

14. Peripheral T-cell lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country

  • 14.1. Phase-II

15. Multiple Non Hodgkin Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country

  • 15.1. Preclinical till Registration
  • 15.2. Marketed Drugs Clinical Insight
  • 15.3. Discontinued Drugs in Clinical Pipeline

16. Competitive Landscape

  • 16.1. Aryogen Biopharma
  • 16.2. Biogen Idec
  • 16.3. Biovest International
  • 16.4. Chugai Pharmaceutical
  • 16.5. Genetech
  • 16.6. ImmunoGen
  • 16.7. Johnson & Johnson
  • 16.8. Novartis
  • 16.9. Pfizer
  • 16.10. Roche

List of Figures:

  • Figure 1-1: Types of Blood Cancer
  • Figure 1-2: Identification of Different Types of Lymphomas
  • Figure 1-3: Classification Systems for Non Hodgkin Lymphoma
  • Figure 1-4: Grading of Non Hodgkin Lymphomas
  • Figure 1-5: Classification of Low Grade Non Hodgkin Lymphomas
  • Figure 1-6: Classification of High Grade Non Hodgkin Lymphomas
  • Figure 2-1: Mechanism of Monoclonal Antibodies for the Treatment of Non Hodgkin Lymphoma
  • Figure 2-2: Mechanism of Kinase Inhibitors for Treating Non- Hodgkin Lymphoma
  • Figure 2-3: Mode of Action of Non Hodgkin Lymphoma Vaccines
  • Figure 3-1: Non-Hodgkin Lymphoma Therapeutics Market (US$ Billion), 2014-2020
  • Figure 3-2: Folicular Lymphoma Clinical Pipeline by Phase (%), 2014
  • Figure 3-3: Folicular Lymphoma Clinical Pipeline by Phase (Number), 2014
  • Figure 3-4: Discontinued Follicular Lymphoma Clinical Pipeline by Phase (%), 2014
  • Figure 3-5: Discontinued Follicular Lymphoma Clinical Pipeline by Phase (Number), 2014
  • Figure 3-6: Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
  • Figure 3-7: Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
  • Figure 3-8: No Development Reported in Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
  • Figure 3-9: No Development Reported in Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
  • Figure 3-10: Discontinued Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
  • Figure 3-11: Discontinued Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
  • Figure 3-12: Suspended Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
  • Figure 3-13: Suspended Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
  • Figure 3-14: B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
  • Figure 3-15: B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
  • Figure 3-16: No Development Reported in B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
  • Figure 3-17: No Development Reported in B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
  • Figure 3-18: Discontinued B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
  • Figure 3-19: Discontinued B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
  • Figure 3-20: Mantle-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
  • Figure 3-21: Mantle-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
  • Figure 3-22: Cutaneous T-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
  • Figure 3-23: Cutaneous T-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
  • Figure 3-24: Discontinued Cutaneous T-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
  • Figure 3-25: Discontinued Cutaneous T-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
  • Figure 3-26: Diffuse Large B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
  • Figure 3-27: Diffuse Large B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
  • Figure 3-28: Discontinued Diffuse Large B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
  • Figure 3-29: Discontinued Diffuse Large B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
  • Figure 3-30: T-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
  • Figure 3-31: T-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
  • Figure 3-32: Mycosis Fungoides Clinical Pipeline by Phase (%), 2014
  • Figure 3-33: Mycosis Fungoides Clinical Pipeline by Phase (Number), 2014
  • Figure 3-34: Multiple Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
  • Figure 3-35: Multiple Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
  • Figure 3-36: Discontinued Multiple Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
  • Figure 3-37: Discontinued Multiple Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
  • Figure 4-1: Drivers for Non- Hodgkin Lymphoma Market
  • Figure 4-2: Challenges for Non- Hodgkin Lymphoma Market
Back to Top